China SFDA Encourages Regulatory Consultations In New Communication Guidelines
This article was originally published in PharmAsia News
China hopes strengthened communication with sponsors will spur innovation and new drug approvals.
You may also be interested in...
China's State FDA increased drug approvals by more than 26% in 2010, with the boost largely due to an increase in generic drug approvals. The agency also cleared more clinical trials for drugs that treat diseases that have a large societal impact, according to SFDA's second annual report on the status of drug approvals
Junshi’s oral antiviral shows signs of effectiveness in treating patients with mild COVID-19 symptoms but more data are needed, caution researchers.
2021 saw a record number of novel drug launches and the size of the pipeline topped 20,000 candidates for the first time, new analysis shows, while China came of age as a pharma player.